Energenesis Biomedical CO.,LTD. (TPE:6657)

Taiwan · Delayed Price · Currency is TWD

30.00

+0.15 (0.50%)

Nov 13, 2026, 1:30 PM CST

Market Cap	2.64B -30.2%
Revenue (ttm)	7.64M -4.4%
Net Income	-298.61M
EPS	-3.38
Shares Out	87.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,150
Open	29.50
Previous Close	29.85
Day's Range	29.50 - 30.40
52-Week Range	27.00 - 59.70
Beta	0.40
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 18, 2026

About TPE:6657

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 35

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 6657

Full Company Profile

Financial Performance

In 2025, TPE:6657's revenue was 7.67 million, a decrease of -0.97% compared to the previous year's 7.75 million. Losses were -258.40 million, 11.8% more than in 2024.

Financial Statements